Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in Unclassifiable Progressive Fibrosing Interstitial Lung Disease
2016-002744-17Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in interstitial lung disease (ILD) comparing Pirfenidone (Esbriet) with Placebo (2 arms). Primary endpoint: Rate of decline in forced vital capacity (FVC) over 24 weeks. Started Mar 2017; status: completed.
02
Drugs
pirfenidone
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on 2016-002744-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002744-17.